NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Mechanism of Action
active, direct H 1 -receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H 1 -receptor and has affinity for the histamine H 2 -receptor. Epinastine also possesses affinity for the ɑ 1 , ɑ 2 -, and 5-HT 2 -receptors.
Indications (1)
Clinical Trials (5)
COVID-19 Study of Safety and Tolerability of Alvelestat
Started Jan 2021
15 enrolled
Covid19
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
Started Apr 2019
63 enrolled
Alpha-1 Antitrypsin Deficiency (AATD)Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I MutationsEmphysema or COPD
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
Started Oct 2018
99 enrolled
Alpha 1-Antitrypsin DeficiencyEmphysemaCOPD
Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
Started Jan 2009
847 enrolled
Conjunctivitis, Allergic
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
Started Jul 2006
84 enrolled
FibrosisLung DiseaseRespiratory Disorders+4 more